Athersys (ATHX) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Citi cuts investment banking analyst program to two years - Bloomberg
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Nasdaq notches record high close as investors focus on earnings
Athersys Reports Second Quarter 2016 Results
August 9, 2016 4:03 PM EDTCLEVELAND, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) today announced its financial results for the three months ended June 30, 2016.
Highlights of the second quarter of 2016 include:
Successful discussions with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) on ischemic stroke study design and requirements, led by HEALIOS K.K. (Healios) with Athersys support, laying the groundwork for study initiation later this year;Productive discussions with U.S. Food and Drug Administration (FDA) about the design of our planned international Phase 3 study of MultiStem® treatment for... More


